INTRODUCTION

The analytical method development is a process of demonstrating that the method developed is proper for its intended use. An accurate and reproducible analytical method proves that the obtained data is true and validated. In this regard, HPLC plays an important role in the separation and quantitative identification of components as raw in single or in a mixture. Amount of drug and their metabolites in the unit of pharmaceutical dosage forms are the main and crucial quality characteristics that help to check and confirm the quality, safety, and efficacy of drug substances and drug products.

Pregabalin is a structural analogue to gamma-aminobutyric acid (GABA), just as with gabapentin (GBP). Initially it was used for the treatment of epilepsy, but latter studies described their usefulness in the treatment of neuropathic pain (NeP). It is chemically described as 5-methyl-hexanoic acid. It is white to off-white crystalline solid, freely soluble in water and in basic and acidic aqueous solution. Due to highly soluble and highly permeable compound; the oral absorption is almost 90% and is not dependent of dose and rate of administration. On the other hand, Pregabalin is classified as a schedule V drug in the U.S under Administrative Controlled Substances Code Number (ACSCN) # 2782. It has narrow therapeutic Index and is highly potent drug. It may cause serious side effects/adverse effects if the percentage content of drug per unit is not as per label claim.

The main efforts of the current study were to modify and validate HPLC analytical method for the determination of pregabalin in their dosage forms, depending on the availability and feasibility of the facilities. Pregabalin is errant in nature, so the reliable scrutiny of active component in its dosage forms is essential to control the content uniformity and to establish the quality and safety of products. To achieve this goal, HPLC is the most used technique. The basic concept of this method was adapted from Indian Pharmacopoeia 2014.

MATERIALS AND METHODS

Materials

Pregabalin was obtained as gift sample from Dr Reddy Laboratories, Hyderabad, India. Potassium hydroxide, hydrochloric acid (Merck), Potassium dihydrogen phosphate (Merck), Sodium Hydroxide (Sigma Aldrich), and distill water was freshly prepared by distillation.
method. PGB capsules (150 mg) were randomly purchased from local market of UAE

**Instruments**

The projected study was completed by using HPLC system comprises of a LC-20AD liquid chromatography equipped with SPD-20A UV-VIS detector. Chromatographic separations were performed on waters column, C18 (3.9 x 300 mm; 10 µm packing) which was attached with loop 20 µl and attached with HPLC-Dell system. Electronic balance (Mettler Toledo, England), pH meter (Hanna).

**Preparation of Mobile phase**

A mixture of Acetonitrile and KH₂PO₄ buffer (pH=6.9) was prepared in the ratio of 50:950. Mobile phase was filtered through filtration unit (Millipore, 0.45 µm pore size) and degassed before use.

**Preparation of Diluent**

Weighed 1.2g of monobasic potassium phosphate and dissolved in 900ml of distilled water. The pH was adjusted to 6.9 ± 0.05 with 5N KOH and volume was made up to 1L with distilled water

**Preparation of Standard solutions**

50 mg of Pregabalin (Ref) powder was weighed accurately and transferred carefully in to 50 ml volumetric flask. It was diluted with diluents and shaken for 5 min. After shaking, 4 ml of solution was pipetted out and was diluted to 25 ml to get the final standard solution of 160 µg/ml. It was filtered through 0.45µm filter paper.

**Specification of HPLC**

Mobile Phase was a mixture of Acetonitrile: KH₂PO₄ (50:950). The separation was carried out at wavelength of 210 nm with flow rate of 1.5 ml/min. System suitability parameters were as per USP³ (2018) i.e included, Theoretical plate numbers > 2000; Tailing factor < 2.0 and Resolution > 2.0 (indicates method variation and column aging) whereas RSD of replicate injections must be < 2.0% gives the idea about the system performance.

**Construction of Calibration curve**

The calibration curve was constructed by using pregabalin (Ref.) powder. Series of different concentrations (250-50 µg/ml) were made in diluent and absorbance of solutions was measured by HPLC at λ = 210 nm.

**Optimization and Validation of HPLC method**

The study was conducted to optimize and validate HPLC analytical method to determine pregabalin. The experiment was carried-out according to the specifications of United State Pharmacopeias³ (USP 41–NF 36, 2018) and validated as per International Conference on Harmonization³ (ICH-1996). The method was validated for the parameters as system suitability, specificity, range and linearity, limit of detection, limit of quantification, accuracy, precision, ruggedness and robustness.

**RESULTS AND DISCUSSION**

To generate a reliable and accurate quantitative data, it is important to evaluate and validate an analytical method to ensure that they produce valid results, appropriate for their intended purpose. Steps involved in experimental procedure must be simple and easy. Depending on the extent of the adjustment, it is essential to understand the nature of compound that help to gather the basic information regarding the sample pre-treatment, ideas about the separation techniques, wavelength for detection and analytical conditions to ensure that they work properly in its local environment.

Pregabalin is freely soluble in water and high polar compound. Beside this, it has narrow therapeutic Index, that means it is highly potent in its function. It may cause major side effects or adverse effects if the amount of drug in their dosage form is not estimated properly. Pregabalin is an antiepileptic drug, functions by binding to the alpha2-delta (a2δ) subunit of the voltage-gated calcium channels. These actions might fluctuate during the transportation of drug from site of administration to site of action due to change of temperature and pH of GIT.

A rapid and accurate method of analysis to get a satisfactory result from pharmaceutical products is the most important part of any research and developments. Adjustment of the capacity factors like analysis time and detection sensitivity, for good chromatographic separation are the challenging point in the optimization of method. In the present study, the focusing point of pregabalin is its high solubility, polarity and UV absorption.

A Reverse phase HPLC isocratic method was developed. The basic component of mobile phase is monobasic potassium phosphate and the idea regarding the selection of this salt was adapted from Indian Pharmacopeia⁷, keeping in mind the system suitability parameters like resolution factor (Rf) between peaks, tailing factor (T), number of theoretical plates (N), runtime and the cost effectiveness.

System suitability tests are an integral part of method development and are used to ensure adequate performance of the chromatographic system. This test is based on feasibility of equipment, analytical procedure and samples used to analyze²¹. System suitability test was done by injecting six replicate injections of standard pregabalin solution of 1mg/ml.

The percentage coefficient of variation (% CV) of the retention times and the peak areas of pregabalin were 0.052% and 0.753% respectively. Whereas the Mean theoretical plates count, based on USP tangent calculations³ for pregabalin peak was 5730.195 (Table 1). The higher plate counts define the efficiency of column, whereas the tailing factor 1.2, indicates almost the symmetrical pictures of peak.
Table 1: Summary of System suitability results for Pregabalin

| Injection Number | Retention Time of Pregabalin (min) | Peak Area of Pregabalin | USP Tailing Factor | USP Tangent |
|------------------|-----------------------------------|-------------------------|--------------------|-------------|
| 1                | 6.583                             | 433339                  | 1.273              | 5760.62     |
| 2                | 6.584                             | 430312                  | 1.269              | 5741.01     |
| 3                | 6.583                             | 428920                  | 1.264              | 5713.46     |
| 4                | 6.577                             | 428878                  | 1.263              | 5717.41     |
| 5                | 6.580                             | 435892                  | 1.266              | 5704.76     |
| 6                | 6.587                             | 435767                  | 1.261              | 5743.91     |
| Mean             | 6.582                             | 432184.7                | 1.266              | 5730.195    |
| % CV             | 0.052                             | 0.753                   | 0.346              | 0.376       |

The calibration curve was linear over the range of 250-50 µg/ml and regression analysis ($R^2$) was calculated by examining the samples of five different concentrations that was found to be 0.9993. The value of $R^2$ indicated that the proposed analytical procedure has ability to give test results (quantitative data) with acceptable level of accuracy and precision (Figure 1).

The ability of method for percent recoveries (accuracy) was calculated by samples solution prepared in triplicate at three levels over a range of 70-130% and performed as per procedure. The recovery ranges were from 97.68 to 102.48% with % CV value of 0.73 to 1.95 % (Table 2).

Table 2: Accuracy data for the assessment of pregabalin

| Level  | Sample Number | Sample Amount (mg) | Pregabalin | % Recovery | % Mean Recovery | % CV |
|--------|---------------|--------------------|------------|------------|-----------------|------|
|        |               |                    | Theoretical mg | Measured mg |                  |      |
| 70%    | 1             | 183.26             | 105.73      | 103.28     | 97.68           |      |
|        | 2             | 183.75             | 106.01      | 106.29     | 100.26          |      |
|        | 3             | 183.68             | 105.97      | 104.37     | 98.49           |      |
| 100%   | 1             | 255.6              | 147.46      | 151.11     | 102.48          |      |
|        | 2             | 262.5              | 151.44      | 151.092    | 99.77           |      |
|        | 3             | 261.3              | 150.75      | 148.74     | 98.67           |      |
| 130%   | 1             | 343.98             | 198.45      | 197.32     | 99.43           |      |
|        | 2             | 338.52             | 195.3       | 196.94     | 100.84          |      |
|        | 3             | 339.17             | 195.68      | 195.28     | 99.8            |      |
| Mean   |               |                    |             |            | 99.71           | 1.34 |

% CV = coefficient of variation (help to precise the estimation)
These results demonstrate the closeness of recovery values from their theoretical values and expressed that the intended method is fast and accurate for the quantification of pregabalin.

Precision of the method was demonstrated at two different levels such as repeatability and intermediate precision. Repeatability was carried out by injecting six (6) consecutive samples of 1000µg/ml of the test concentration (system suitability), that help to understand the operating conditions of equipment over a short period of time, as the result is tabulated in Table 1. It is also expressed as inter and intra-day assay.

The repeatability of the method was checked by injecting three different concentrations at different time intervals within a day or in different days. The tabulated results of all the samples (Table 3 & 4) were calculated for % CV and were found to be 0.46–0.79 and 0.072–1.37 respectively, which was well within the acceptance limit of ≤ 2%.

### Table 3: Intra-day variation in the analysis of Pregabalin

| Conc. (µg/ml) | 9.00 am | 12.0 am | 3.00 am | Mean          | ±SD | % CV  |
|---------------|---------|---------|---------|---------------|-----|-------|
| 50            | 21052   | 20674   | 20720   | 20815.33      | 206.25 | 0.99     |
| Mean          | 21014   | 20889   | 20788.5 | 20897.2       | 112.97 | 0.54     |
| 100           | 42337   | 42467   | 43038   | 42614         | 372.90 | 0.88     |
| Mean          | 42542   | 42469.5 | 43052   | 42687.83      | 335.09 | 0.79     |
| 150           | 63576   | 63148   | 63980   | 63568         | 416.06 | 0.65     |
| Mean          | 63496   | 63515   | 64014   | 63675         | 293.74 | 0.46     |

±SD = Standard deviation (Measures the amount of variability)

### Table 4: Inter-day variation in the analysis of Pregabalin

| Concentration (µg/ml) | 1st day | 2nd day | 3rd day |
|-----------------------|---------|---------|---------|
| 50                    | 21077   | 21077   | 20936   |
| Mean                  | 21763   | 21077   | 20936   |
| % CV                  | 1.37    | 0.46    | 0.41    |
| 100                   | 42337   | 43116   | 42718   |
| Mean                  | 42542   | 43094   | 42907   |
| % CV                  | 0.68    | 0.072   | 0.62    |
| 150                   | 63980   | 63917   | 63535   |
| Mean                  | 64048   | 63429   | 63614   |
| % CV                  | 0.075   | 0.54    | 0.088   |

Intermediate precision of the method, as per ICH guidelines also known as reproducibility / inter-laboratory trial, was carried out by different analyst in different laboratory (Department of Pharmaceutics, Institute of Pharmaceutical Sciences, Jinnah Sindh Medical University, Karachi, Pakistan), using different HPLC column and system (Table 5). The shorter retention time of method illustrating lower solvent consumption, made it easy to implement daily in routine QC analysis. It is also leading that the procedure is environmentally friendly and allows the analysis of large number of samples in a short period of time which is supporting the need of study.

The result of samples by using different HPLC system, was calculated for % CV, was found between 0.28-4.96%. It indicates that the method adequately meets the acceptance criteria for inter-batch precision which is appropriately less than 15%. The %CV of LLOQ concentration is 4.96%, which is also within the acceptance limit of ≤ 20% (Table 5).
Table 5: Intermediate Precision Data of Pregabalin

| Nominal True Concentration (µg/mL) | Measured Value (µg/mL) | % Result | Statistical Analysis |
|-----------------------------------|------------------------|----------|---------------------|
| 10                                | 10.702                 | 107      | 102.1 ± 5.06        |
|                                   | 9.69                   | 96.9     | 98.1 ± 0.27         |
| 50                                | 49.04                  | 98.08    | 99.59 ± 0.78        |
|                                   | 49.19                  | 98.38    | 99.89 ± 0.87        |
|                                   | 48.92                  | 97.84    | 99.21 ± 0.74        |
| 100                               | 98.69                  | 98.69    | 99.77 ± 1.634       |
|                                   | 100.01                 | 100.01   | 99.77 ± 1.634       |
|                                   | 100.07                 | 100.07   | 99.77 ± 1.634       |
| 150                               | 148.82                 | 99.21    | 99.77 ± 1.634       |

% CV = Coefficient of variation (help to precise the estimation); ±SD = Standard deviation (Measures the amount of variability)

For more verification and validation Robustness study was also carried out on a sample concentration of 160 µg/ml by making slight changes in flow rate, concentration of acetonitrile and change in pH of mobile phase (Table 6). The results demonstrated that there were no significant variations due to the changes in flow rate from 1.0 ml/min. to 1.5 ml/min, with % CV 0.26- 0.078, due to change in pH from 6.7 to 6.9, with coefficient variation of 0.773-0.74 % and the variation in the concentration of acetonitrile from 3.5 to 5.0 % indicated a recovery of 99.77 and 99.8% with % CV 0.071 and 1.634 respectively.

Table 6: Results for Pregabalin Robustness Test

| Parameter               | Changes          | % Target | % Recovery | %CV  |
|-------------------------|------------------|----------|------------|------|
| Target Conditions       |                  | 100.73   | 99.93      | 0.57 |
| Flow rate               | 1.0 ml/min       | 100.0    | 99.63      | 0.26 |
|                         | 1.5 ml/min       | 100.2    | 100.31     | 0.078|
| Buffer pH               | 6.7              | 101.5    | 100.4      | 0.773|
|                         | 6.9              | 100.7    | 99.66      | 0.74 |
| Acetonitrile Variation  | 5 %              | 102.1    | 99.77      | 1.634|
|                         | 3.5 %            | 99.9     | 99.8       | 0.071|

% CV = Coefficient of variation (help to precise the estimation)

Limit of detection (LOD) and Limit of quantification (LOQ) were also done based on peak responses of standard solution in the range of 20-1.0 µg/ml, in which LOQ (1.0 µg/ml) and LOD 0.25 µg/ml respectively with R² = 0.9994 (Figure 2). The value of LOD and LOQ was supported by the study of Kasawar and Farooqui14, 2010.

Analysis of Pregabalin in their dosage form was also verified by the intended method. It is simple, easy and cost-effective method. After validation, it was applied for the assessment of active compound in its capsule dosage form. Retention time was between 6-7 minutes that indicated the effectiveness and suitability of method for routine quality control analysis of finish products.
Stability
The standard solution of 160 µg/ml of pregabalin was kept in refrigerator for 7 days to estimate the possibility of decomposition of API in solution form. The results of analysis showed that the solution was relatively stable with % CV of 0.0086 - 0.234 (Table 7).

Table 7: Stability study of Pregabalin solution

| Sample | Day 0   | Day 1   | Day 3   | Day 7   |
|--------|---------|---------|---------|---------|
| Assay-1| 73109   | 72325   | 73404   | 72568   |
| Assay-2| 73046   | 72125   | 73413   | 72328   |
| MEAN   | 73077.5 | 72225   | 73408.5 | 72448   |
| ± SD   | 44.55   | 141.42  | 6.36    | 169.71  |
| % CV   | 0.06    | 0.196   | 0.0086  | 0.234   |

% CV = Coefficient of variation (help to precise the estimation); ±SD = Standard deviation (Measures the amount of variability)

The study revealed that no significant degradation has occurred in pregabalin solution. The retention time and peak area of solution were almost unchanged, indicating that the application of Pregabalin sample (in mobile phase), can be used for the QC analysis without facing stability issue.

CONCLUSION
The good point of this method is its simplicity, without any change in the analyte properties or increasing the phase of analysis (derivatization), the sample can be prepared in one step and can be used for routine QC analysis of pregabalin in their dosage form. The retention time is only 6-7 minutes, so large number of samples can be run in the same day. The method is isocratic and the quantity of organic solvent used is very small (5ml/100), therefore the method is nonhazardous, economical or cost effective also. The inter day, intraday and short-term stability study indicated that the validated method is good enough with the quality of reproducibility and repeatability. It was concluded that the modified method can be used confidently for the precise and accurate analysis of Pregabalin

Acknowledgments: The authors would like to thank Dr. S. Gurumadhva Rao (President), Dr. Padma Rao (Dean) and Dr. Venkat Ramesh (Chairperson), Department of Pharmaceutics, RAK College of Pharmacy, RAK Medical and Health Sciences University, Ras Al Khaimah, for continuous encouragement and support.

REFERENCES
1. Brawek B., Loffler M., Weyerbrock A., Feuerstein T. Effects of gabapentin and pregabalin on K+-evoked 3H-GABA and 3H-glutamate release from human neocortical synaptosomes. Naunyn Schmiedebergs Arch PharmacoL. 2009; 379(4): 361–69. DOI: 10.1007/s00210-008-0370-z; PMID: 19002437
2. Mellick, G. and Mellick, L. Reflex sympathetic dystrophy treated with gabapentin. Arch Phys Med Rehabil. 1997; 78(1): 98–105. DOI: 10.1016/s0003-9993(97)90020-8; PMID: 9014968
3. Mellick, G., Mellick, L. and Mellick, L. Gabapentin in the management of reflex sympathetic dystrophy. J Pain Symptom Manage 1995; 10(4): 265–266. DOI: 10.1016/0885-3924(95)00001-F; PMID: 7602177
4. Mellick, L. and Mellick, G. Successful treatment of reflex sympathetic dystrophy with gabapentin. Am J Emerg Med 1999; 13(1): 36. DOI: 10.1016/0735-6757(98)00263-5; PMID: 9732967
5. Lyrica (Pregabalin) package insert. (2005) New York, NY: Pfizer, Inc., Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021446s002s003ib
6. Drug Enforcement Administration, Department of Justice. Schedules of controlled substances: Placement of pregabalin into Schedule V. Final Rule. Fed Regist. 2005; 70(144): 43633-5. https://www.ncbi.nlm.nih.gov/pubmed/16050051
7. Indian Pharmacopoeia, Vol. 3. The Indian Pharmacopoeia Commission, Ghaziabad. 2014; p. 2548-2552.
8. United States Pharmacopeia and National Formulary USP 41–NF 36, Vol.4; < 621> Chromatography. The United States Pharmacopeial Convention, Inc. Rockville, MD 20852. 2018; p. 6363-6375
9. ICH guidelines Topic Q2 (R1) Validation of analytical procedures: methodology. London, 1996. Available from: https://www.ema.europa.eu/en/documents/scientificguideline/ich-q2-r1-validation-analytical-procedures-text-methodology-step-5.en
10. Taylor CP, Angelotti T, Fauman E. Pharmacology and mechanism of action of pregabalin: The calcium channel alpha2-delta (alpha2-delta) subunit as a target for antiepileptic drug discovery. Epilepsy Res. 2007; 73(2):137–50. DOI: 10.1016/j.eplepsyres.2006.09.008; PMID: 17126531
11. Balaji J., Ramachandra B., Naidu N.V.S. Analytical RP-HPLC Method for Development and Validation of Pregabalin in Bulk and the determination of Pregabalin in capsule dosage form. UIRSET. 2014; 3(4): 11094-8
12. Arayne S.M, Shahnaz H., Ali A., and Sultana N. Monitoring of Pregabalin in Pharmaceutical Formulations and Human Serum Using UV and RP-HPLC Techniques: Application to Dissolution Test Method. Pharm Anal Acta 2014, 5(2): 1000287- 94. DOI: 10.4172/2153-2435.1000287
13. Guidance for industry Q2B Validation of Analytical Procedures: Methodology FDA US, Available from: http://www.fda.gov/downloads/Drugs/guidanceregulatoryinformation/ guidances/ucm073384
14. Kasawar G. B. and Farooqil M. N. Development and Validation of HPLC Method for the Determination of Pregabalin in Capsules. Indian J. Pharm. Sci. 2010; 72(4):517-19. DOI: 10.4103/0250-474X.73935; PMID: 21218069

Source of Support: The author(s) received no financial support for the research, authorship, and/or publication of this article.

Conflict of Interest: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

For any question relates to this article, please reach us at: globalresearchonline@rediffmail.com
New manuscripts for publication can be submitted at: submit@globalresearchonline.net and submit_ijpsrr@rediffmail.com